Shuangshuang Yao
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα.
Journal: Metabolism: clinical and experimental
Published: December 07, 2025
KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα.
Journal: Metabolism: clinical and experimental
Published: December 07, 2025
LGR4 is a key regulator of hepatic gluconeogenesis.
Journal: Free radical biology & medicine
Published: November 26, 2024
USP13 ameliorates metabolic dysfunction-associated steatohepatitis through targeting PTEN.
Journal: Life sciences
Published: September 22, 2024
USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1.
Journal: Journal of translational medicine
Published: March 24, 2024
Erratum: Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice.
Journal: iScience
Published: September 11, 2023
Interrelation between the lipid accumulation product index and diabetic kidney disease in patients with type 2 diabetes mellitus.
Journal: Frontiers in endocrinology
Published: May 18, 2023
Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice.
Journal: iScience
Published: June 09, 2022
Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle.
Journal: Free radical biology & medicine
Published: July 20, 2020
PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation.
Journal: Cell death & disease
Published: November 28, 2018
Protective effects of protopanaxatriol on acute liver injury induced by concanavalin A.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: May 09, 2018
miR199a-5p inhibits hepatic insulin sensitivity via suppression of ATG14-mediated autophagy.
Journal: Cell death & disease
Published: September 25, 2017
Last Updated: 09/26/2026